cBAT - CBAT

La vendita allo scoperto per CBAK Energy Tech dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di CBAK Energy Tech. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

CBAK Energy Tech (NASDAQ:CBAT) Azioni, Report sulle vendite allo scoperto

CBAK Energy Tech

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

CBAK Energy Technology, Inc. - Common Stock

CBAK Energy Technology Inc

JP Morgan analyst DS Kim maintains TAL Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) with a Overweight and lowers the price target from $17 to $16.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on TAL Education, Lowers Price Target to $16

JP Morgan analyst Anthony Elian maintains Synovus Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Overweight and lowers the price target from $54 to $50.

JP Morgan Maintains Overweight on Synovus Financial, Lowers Price Target to $50

JP Morgan analyst Casey Woodring maintains QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Underweight and lowers the price target from $38 to $25.

QDEL

JP Morgan Maintains Underweight on QuidelOrtho, Lowers Price Target to $25

RBC Capital analyst Andrew Wong maintains Aclara Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ARA#TSX">ARA</a>) with a Sector Perform and raises the price target from C$0.7 to C$0.85.

TSX:ARA

RBC Capital Maintains Sector Perform on Aclara Resources, Raises Price Target to C$0.85

JP Morgan analyst DS Kim maintains New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) with a Neutral and lowers the price target from $50 to $48.

New Oriental Education & Technology Group

JP Morgan Maintains Neutral on New Oriental Education, Lowers Price Target to $48

Food safety company Neogen Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) on Monday agreed to sell its global cleaners and disinfectants business to Kersia Group.
Kersia offers biosecurity, disinfection <a href="https://www.benzinga.com/pressreleases/25/04/b44896153/neogen-announces-sale-of-cleaners-disinfectants-business" target="_blank" rel="noreferrer noopener">and hygiene solutions</a>.
Deal consideration consists of $130 million in cash at closing plus contingent consideration tied to the future performance of the business.
Neogen says the transaction is expected to be accretive to margins and close in the first quarter of the company&#8217;s 2026 fiscal year.
The net proceeds will be used to fully repay the $100 million drawn on the company&#8217;s revolving credit facility in the recent term loan refinancing, with the divestiture expected to reduce the company&#8217;s net leverage ratio by approximately 0.4x on a pro forma basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44709995/neogen-q3-earnings-fall-short-on-expectations-cuts-guidance-amid-macro-headwinds-and-tariff-concerns" rel="noreferrer noopener">Neogen Q3 Earnings Fall Short On Expectations, Cuts Guidance Amid Macro Headwinds And Tariff Concerns</a>
&#8220;The sale of our cleaners and disinfectants business further focuses Neogen on food safety diagnostics and continuing to build on our leadership position in what we believe is an attractive end market with long-term tailwinds,&#8221; said John Adent, president and CEO of Neogen. 
&#8220;The cleaners and disinfectants business has been a strong contributor to our Animal Safety segment and Neogen is committed to a smooth transition for customers, employees and other stakeholders. We expect Kersia&#8217;s prioritization of investment and growth in the biosecurity market will benefit the business and provide sharpened strategic focus to maximize its potential for continued growth.&#8221;
With approximately $60 million in annual revenue, Neogen&#8217;s cleaners and disinfectants are used in a range of livestock applications, including swine, poultry, and ruminant operations.
Earlier this month, Neogen refinanced the remaining $550 million principal of its original $650 million term loan, as well as its revolving credit facility, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44665667/neogen-announces-refinancing-of-term-loan-and-revolving-credit-facility" rel="noreferrer noopener">due in August 2027</a>.
The new $450 million term loan and $250 million revolving credit facility mature in April 2030, extending the previous maturity by over two and a half years.
With an upsizing of the company&#8217;s revolving credit facility from $150 million to $250 million and an initial draw of $100 million, the refinancing represents a leverage-neutral transaction.
&#8220;We are pleased to complete this refinancing, which not only maintains our current liquidity position and extends the maturity of the term loan and revolving credit facility, but also results in a lower interest rate,&#8221; said David Naemura, CFO and COO of Neogen.
NEOG Price Action: Neogen stock is up 4.90% at $4.61 at publication on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44894989/astrazeneca-daiichi-sankyos-multi-billion-dollar-cancer-drug-shows-superior-efficacy-across-broad-her2-positive-metastatic-breast-cancer-patients" target="_blank" rel="noreferrer noopener">AstraZeneca- Daiichi Sankyo&#8217;s Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients</a></li>
</ul>
Photo: Shutterstock

Health Care

General

NEOG

Neogen Seeks To Cut Debt, Streamline Focus With Sale Of Cleaners, Disinfectants Business For $130 Million

WIIM

UBER

Uber shares are trading lower after the FTC filed a lawsuit against the company.

JP Morgan analyst Andrew Steinerman maintains ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) with a Neutral and lowers the price target from $65 to $50.

JP Morgan Maintains Neutral on ManpowerGroup, Lowers Price Target to $50

Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares are trading lower on Monday amid reports indicating the company stopped exporting certain high-end vehicles to China <a href="https://www.benzinga.com/25/04/44888445/ford-reportedly-halts-vehicle-shipments-to-china-amid-rising-tariffs">due to tariffs.</a>
What To Know: The automobile giant has stopped shipments of its F-150 Raptors, Mustangs, Michigan-built Bronco SUVs and Kentucky-made Lincoln Navigators to China, according to Reuters. The move comes as retaliatory tariffs under President Donald Trump's administration reach as high as 150% on some vehicles.
The tariffs are expected to raise prices and limit demand.
The stock may be trading lower following the announcement, as investors consider the potential impact on revenue from reduced China sales. While China sales represent a small slice of Ford's overall business, the exports have been consistently profitable.
Notably, Ford may be better positioned to manage tariffs than some competitors, as it builds about 80% of the vehicles it sells in the U.S. domestically. Still, the company is expected to raise prices.
See Also: <a href="https://www.benzinga.com/25/04/44903087/amazon-stock-downgraded-price-target-slashed-as-tariffs-create-uncertainty">Amazon Stock Downgraded, Price Target Slashed As Tariffs Create Uncertainty</a>
F Price Action: At the time of writing, Ford shares are trading 2.75% lower at $9.36, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

Movers

What's Going On With Ford Stock Monday?

JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Neutral and lowers the price target from $70 to $68.

INCY

JP Morgan Maintains Neutral on Incyte, Lowers Price Target to $68

JP Morgan analyst Jeremy Tonet maintains Gibson Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GEI#TSX">GEI</a>) with a Underweight and lowers the price target from C$23 to C$22.

TSX:GEI

JP Morgan Maintains Underweight on Gibson Energy, Lowers Price Target to C$22

RBC Capital analyst Karl Shepard maintains Synovus Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Outperform and lowers the price target from $64 to $52.

RBC Capital Maintains Outperform on Synovus Financial, Lowers Price Target to $52

JP Morgan analyst Michael Rehaut maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Underweight and lowers the price target from $132 to $111.

JP Morgan Maintains Underweight on D.R. Horton, Lowers Price Target to $111

<a href="https://www.theinformation.com/articles/palo-alto-networks-offers-smooth-ride-turbulent-markets" title="https://www.theinformation.com/articles/palo-alto-networks-offers-smooth-ride-turbulent-markets">https://www.theinformation.com/articles/palo-alto-networks-offers-smooth-ride-turbulent-markets</a>

PANW

'Palo Alto Networks Offers A Smooth Ride In Turbulent Markets' - The Information

RBC Capital analyst Karl Shepard maintains Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Outperform and lowers the price target from $20 to $18.

HBAN

RBC Capital Maintains Outperform on Huntington Bancshares, Lowers Price Target to $18

<a href="https://www.ftc.gov/news-events/news/press-releases/2025/04/ftc-takes-action-against-uber-deceptive-billing-cancellation-practices" title="https://www.ftc.gov/news-events/news/press-releases/2025/04/ftc-takes-action-against-uber-deceptive-billing-cancellation-practices">https://www.ftc.gov/news-events/news/press-releases/2025/04/ftc-takes-action-against-uber-deceptive-billing-cancellation-practices</a>

Legal

'FTC Takes Action Against Uber For Deceptive Billing And Cancellation Practices; Says Company Enrolled Consumers In Subscription Service And Charged Them Without Their Consent, Made It Difficult For Users To Cancel'

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Neutral and raises the price target from $55 to $58.

HALO

JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $58

RBC Capital analyst Karl Shepard maintains Home BancShares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOMB#NYSE">HOMB</a>) with a Sector Perform and lowers the price target from $33 to $31.

HOMB

RBC Capital Maintains Sector Perform on Home BancShares, Lowers Price Target to $31

Editor&rsquo;s note: This article was originally published in June 2024. It has been updated as of April 2025 to reflect the latest developments in Marlon Wayans&rsquo; partnership with Dr. Green NFT.
&quot;When you get older, you do it with purpose,&quot; says <a href="https://elplanteo.com/marlon-wayans-cannabis-entrevista/">Marlon Wayans</a> in an exclusive interview, reflecting on his evolving relationship with <a href="https://www.benzinga.com/cannabis">cannabis</a>. The multi-talented actor, comedian, and producer, known for his iconic roles in weed-forward films like &quot;Scary Movie&quot; and &quot;Don&#39;t Be a Menace to South Central While Drinking Your Juice in the Hood,&quot; has seen his use of cannabis transition from youthful experimentation to a purposeful part of his lifestyle.
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" frameborder="0" height="315" src="https://www.youtube.com/embed/CK-rJrytmJE?si=vUOIW6C4IV_EpCn5&amp;start=17" width="560"></iframe>
He openly shares how his perspective has matured over the years. &quot;When you&#39;re younger, you just smoke because you like smoking; you want to get high and be with your friends,&quot; he explains. &quot;When you get older, it&#39;s like, okay, I&#39;m gonna do this strain because I want to just relax right now. I want this kind of weed because I just want to chill right now and have some fun.&quot; This evolution mirrors the broader societal shift towards understanding and embracing the multifaceted uses of cannabis, beyond mere recreation.
Also read:&nbsp;<a class="post-card-article-link" href="https://www.benzinga.com/markets/cannabis/25/04/39797136/tiffany-haddish-if-men-had-period-pain-weed-would-already-be-legal">Tiffany Haddish: &#39;If Men Had Period Pain, Weed Would Already Be Legal&#39;</a>
Calling from his home in Los Angeles, Wayans is in the midst of a busy schedule, juggling film shoots and stand-up shows. &quot;I&#39;ve been crazy. I was filming a movie&hellip; then wrapping the movie, then doing stand-up shows and promoting my special,&quot; he says. He recently finished filming a psychological horror movie directed by Justin Tipping and written by Jordan Peele, which is set to release in September 2025. &quot;I finally am home. I was in Albuquerque filming a Jordan Peele movie. I got the lead in this movie called &#39;Him&#39;&hellip; It got me in shape and I&#39;m happy about that because I play a football player. It&#39;s a great role, a great movie.&rdquo;
Despite his hectic life, Wayans makes time for projects that align with his passions, one of which is his partnership with <a href="https://drgreennft.com/platinum-holders/marlon-wayans" rel="nofollow noopener noreferrer" target="_blank">Dr. Green NFT</a>.
<h3>Business, Health, Relaxation, Creativity: One Plant Fits All</h3>
Wayans&#39; connection with Dr. Green NFT, spearheaded by British-Jamaican entrepreneur Maximillian White, marks his formal entry into the cannabis industry. His decision to join the project was carefully considered. &quot;I&#39;ve been offered a lot of deals. I was talking to a few people. I chose Dr. Green because I felt like this company actually knows what they&#39;re talking about,&quot; Wayans notes.
Today, Wayans holds a Platinum Digital Key within the Dr. Green ecosystem, granting him exclusive access to his own custom cannabis strain and distribution channel. &quot;What we&#39;re gonna do with the likes of Marlon is we&#39;re gonna ask him what he wants to see from his marijuana. We&#39;re gonna build him a specific strain set for him. Nobody else on the planet&#39;s gonna have that,&quot; White explains.
For Wayans, cannabis is not just about personal enjoyment; it&rsquo;s a tool for creativity and well-being. &quot;Sometimes it&#39;s just to relax, sometimes it&#39;s when I want to write,&quot; he shares. &quot;I want to think creatively and allow my mind to expand, so I smoke a specific strain or take a specific gummy.&quot;
Wayans&#39; advocacy extends beyond personal use as he addresses systemic issues. He is acutely aware of the racial biases that have marred the history of cannabis legislation and enforcement in the United States. &quot;A lot of my friends used to get pulled over and get in trouble for smoking weed,&quot; he recalls, pointing out the&nbsp;<a href="https://www.aclu.org/publications/report-war-marijuana-black-and-white" rel="nofollow noopener noreferrer" target="_blank">disproportionate impact on Black and Brown communities</a>. While acknowledging the progress made, he insists there&#39;s still a long way to go in ensuring equitable treatment and opportunities within the industry.
Additionally, he is a strong proponent of the plant&rsquo;s therapeutic value. &quot;I have two friends battling cancer right now and when they&#39;re in severe pain, exactly what they do is get them some cannabis, and it&#39;s the only thing that stops the pain,&quot; he says.
Reflecting on his career, Wayans discusses how cannabis has influenced his work: &quot;For me, I always like the movies I make, and it&#39;s funny. It&#39;s not on purpose, but we made movies for weedheads. If you look at &#39;Scary Movie,&#39; Shorty, the character, was literally every dude I knew in the 90s wrapped up in one.&quot;
&quot;My message is always gonna be life, love, and laughter, no matter what I do. Over the years, I&rsquo;ve fed a lot of laughs to my audience. So when it comes to me and marijuana, I&#39;m bringing the fun, the laughs, the jokes, the silly, the creative&hellip; all the good things that I extracted from the culture. I&#39;m giving back to the culture and looking forward to making more movies, smoking and having my marijuana, and making myself loud, smoking my own marijuana tomorrow.&quot;
His involvement with Dr. Green NFT has also provided an educational opportunity. In 2024, Wayans toured the company&rsquo;s cultivation and research facilities in Portugal, where he learned firsthand about cannabis genetics, seed-to-sale traceability, and blockchain integration. &quot;This is school. I&#39;m going to weed school,&quot; he said at the time.
<h3>Dr. Green NFT: Where Blockchain Meets Cannabis</h3>
Dr. Green NFT integrates blockchain technology with cannabis cultivation and distribution, addressing product authenticity and access. The company&rsquo;s Digital Keys act as virtual licenses, allowing holders to participate in cannabis distribution without owning a physical business. Entry-level keys start around $10,000 and provide access to Dr. Green&rsquo;s infrastructure &mdash; from licensing and compliance to packaging and logistics.
Unlike traditional models, Dr. Green NFT avoids retail storefronts. Instead, NFT holders function as wholesale partners. &quot;We don&#39;t want speculative holders. We&#39;re not an investment product,&quot; CTO Ricardo Capone explains. &quot;We want them to buy [the NFT] and use it to transact cannabis.&quot;
One of the company&rsquo;s most innovative features is bespoke medicine. Through DNA analysis, Dr. Green&rsquo;s research labs in Portugal create personalized cannabis treatments for conditions like epilepsy or Parkinson&rsquo;s. &quot;We analyze saliva samples and tailor the cannabinoids and terpenes accordingly,&quot; says Capone.
The European cannabis market is expected to surpass &euro;123 billion by 2028, according to&nbsp;<a href="https://prohibitionpartners.com/reports/the-european-cannabis-report-4th-edition/" rel="nofollow noopener noreferrer" target="_blank">Prohibition Partners</a>. Dr. Green NFT positions itself at the intersection of that growth, combining transparency, tech and access &mdash; and figures like Wayans help amplify the mission globally.
<h3>&lsquo;Cannabis Criminalization Was Always A Tool&rsquo;</h3>
Wayans&rsquo; commitment to Dr. Green NFT is not just about business; it reflects a deeper belief in social justice. &quot;The criminalization of cannabis&hellip; it&rsquo;s always an excuse for Black and Browns to be arrested and to be messed with by cops,&quot; he asserts. By lending his name and platform to an equity-minded cannabis tech company, Wayans hopes to help democratize access and education around the plant.
Maximillian White, Dr. Green&rsquo;s founder, shares that vision. &quot;My retirement now over the next few years is giving back to marijuana what I took from marijuana and making sure that we&#39;ve got a revolution,&quot; he says. &quot;We&#39;re gonna legalize this and make sure that every European country allows people to buy it legally. It&#39;s controlled; they can use their money for tax purposes.&quot;
With a focus on transparency, technology, and community, the partnership between Wayans and Dr. Green NFT represents a new blueprint for how celebrities can influence &mdash; and shape &mdash; the cannabis space for the better.
Disclosure: The content of this article is for informational purposes only and should not be considered investment advice. Please consult a licensed professional before making financial decisions.
Follow me on&nbsp;<a href="https://www.twitter.com/javierhasse" rel="nofollow noopener noreferrer" target="_blank">Twitter</a>&nbsp;or&nbsp;<a href="https://www.linkedin.com/in/javierhasse/" rel="nofollow noopener noreferrer" target="_blank">LinkedIn</a>.&nbsp;Check out&nbsp;my&nbsp;<a href="https://elplanteo.com/" rel="nofollow noopener noreferrer" target="_blank">website</a>&nbsp;or&nbsp;some of my other work&nbsp;<a href="https://benzinga.com/cannabis" rel="nofollow noopener noreferrer" target="_blank">here</a>.&nbsp;
This article was originally published on <a href="https://www.forbes.com/sites/javierhasse/2024/06/07/marlon-wayans-tackles-hard-hitting-questions-as-he-joins-cannabis-mogul-in-new-venture-all-about-giving-back-to-the-culture/">Forbes</a> and appears here with permission.&nbsp;The article is from an external source. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.
Photo: Shutterstock

Cannabis

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Entertainment

Markets

Tech

Interview

Marlon Wayans Talks Selling Weed On The Blockchain: Is Dr. Green Legit? He Isn't Afraid To Answer The Tough Questions

<h3>Gainers</h3>
<ul>
<li>SHF Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) shares increased by 72.2% to $3.84 during Monday's regular session. The market value of their outstanding shares is at $10.6 million. </li>
<li>Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) shares moved upwards by 38.6% to $12.04. The company's market cap stands at $151.0 million. </li>
<li>Ohio Valley Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVBC#NASDAQ">OVBC</a>) shares rose 12.78% to $40.04. The market value of their outstanding shares is at $188.6 million. </li>
<li>Innventure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) stock moved upwards by 12.57% to $3.57. The market value of their outstanding shares is at $168.0 million. </li>
<li>MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNGD#NYSE">FNGD</a>) shares increased by 10.57% to $18.34. </li>
<li>Waton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTF#NASDAQ">WTF</a>) shares moved upwards by 10.33% to $7.15. The market value of their outstanding shares is at $344.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CaliberCos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) shares fell 23.9% to $0.23 during Monday's regular session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) shares declined by 14.31% to $38.39. The company's market cap stands at $1.2 billion. </li>
<li>AGM Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) stock declined by 13.9% to $0.03. The market value of their outstanding shares is at $1.0 million. </li>
<li>Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) stock declined by 13.69% to $0.23. The company's market cap stands at $2.0 million. </li>
<li>Janover (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) shares decreased by 13.01% to $46.0. The market value of their outstanding shares is at $65.7 million. </li>
<li>Webull (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) shares fell 12.93% to $22.93. The company's market cap stands at $10.5 billion. 
See Also: <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGMH

BENF

BULL

FNGD

FRGE

JNVR

OVBC

SEZL

SHF Holdings, Inc. - Class A Common Stock

SHFS

12 Financials Stocks Moving In Monday's Intraday Session

Earnings

Commodities

Press Releases

CBAK Energy Reports Third Quarter & First Nine Months of 2024 Unaudited Financial Results

Contracts

CBAK Energy Technology, Inc. Announces Significant Orders from Anker Innovations, totaling around USD 30 Million to 35 Million

CBAK Energy Announces Expansion in Nanjing: Equipment Procurement Completed and Trial Production Set for May 2025, Adding 3GWh of Capacity

CBAK Energy Announces Collaboration with Ather Energy, one of India's top five electric two-wheeler manufacturers

CBAK Energy's 32140 Cells Capture 19% of Global Market Share, Report Shows

CBAK Energy to Participate at Upcoming Jefferies 6th Asia Forum in Hong Kong

CBAK Energy to Report fourth quarter & full year 2024 Unaudited Financial Results on Monday, March 17, 2025

CBAK Energy Reports Full Year of 2024 Unaudited Financial Results

Kandi and CBAK Announce Strategic Partnership to Launch U.S. Lithium Battery Facilities in Phases

CBAK Partners with Kandi to Localize Lithium Battery Facilities in the U.S. in Phases

CBAT

KNDI

Asia Pacific Wire & Cable Corporation Limited - Common shares, Par value .01 per share

Comments

CBAK Energy Tech

Vendite allo scoperto

CBAK Energy Tech (NASDAQ:CBAT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO